Your Patient Needs Hadlima — Here's How to Help Them Get It

You've prescribed Hadlima (Adalimumab-bwwd) for your patient, and now they're calling back: their pharmacy doesn't have it, or their insurance is requiring a different product, or they simply can't figure out how to get it. This is an increasingly common scenario as the Adalimumab biosimilar market matures.

This guide is designed to help physicians, nurse practitioners, physician assistants, and clinical staff navigate the practical challenges of getting Hadlima into patients' hands. We'll cover the current availability landscape, actionable steps your team can take, alternatives when Hadlima isn't accessible, and workflow strategies to prevent access problems before they start.

Current Availability of Hadlima

As of early 2026, Hadlima is commercially available in the United States but is not uniformly stocked across all pharmacy settings:

• Specialty pharmacies: Generally maintain reliable stock. This is the primary distribution channel for Hadlima and most Adalimumab biosimilars.
• Retail chain pharmacies: Inconsistent stocking. Many chains carry only their PBM's preferred biosimilar, which may or may not be Hadlima.
• Independent pharmacies: Can special-order from wholesalers, typically within 1-2 business days, but rarely carry it on the shelf.
• Hospital/institutional pharmacies: May stock the institutional vial (40 mg/0.8 mL) depending on their formulary.

Hadlima is not currently on the FDA's drug shortage list. The access problems patients experience are primarily related to distribution patterns and formulary decisions rather than manufacturing supply issues.

Why Patients Can't Find Hadlima

Understanding the root causes helps your team troubleshoot more effectively:

Formulary Mismatches

The patient's insurance plan may prefer a different Adalimumab biosimilar. When the pharmacy runs the claim for Hadlima and it's rejected or requires high cost-sharing, the pharmacy may tell the patient it's "not available" when the real issue is coverage, not supply.

Retail vs. Specialty Pharmacy Confusion

Many plans mandate specialty pharmacy dispensing for biologics. If the prescription is sent to a retail pharmacy, it may be rejected — not because of stock, but because of benefit design. Patients often interpret this as a shortage.

Pharmacy Stocking Practices

Pharmacies stock based on demand and formulary contracts. A pharmacy that dispenses primarily through one PBM may only stock that PBM's preferred biosimilar. Hadlima may be available through the same pharmacy's wholesaler but not kept on the shelf.

Patient Knowledge Gaps

Many patients are unfamiliar with biosimilars and may not understand the difference between "my pharmacy doesn't carry it" and "it's not available anywhere." Education is key.

What Providers Can Do: 5 Actionable Steps

Step 1: Verify Insurance Coverage Before Prescribing

Before writing the prescription, have your staff check which Adalimumab products are preferred on the patient's formulary. This can prevent the most common access problem — prescribing a non-preferred product.

• Use your EHR's formulary lookup if available
• Call the PBM or specialty pharmacy directly
• Ask the patient to call their insurance and verify which biosimilars are covered at the lowest tier

Step 2: Route the Prescription to the Right Pharmacy

For most patients, this means sending the prescription to their insurance-designated specialty pharmacy, not their local retail pharmacy. Common specialty pharmacies include:

• Accredo (Express Scripts)
• CVS Specialty
• OptumRx Specialty
• AllianceRx Walgreens
• Biologics by McKesson

If you're unsure which specialty pharmacy the patient should use, their insurance card often lists a specialty pharmacy number, or your staff can call the plan directly.

Step 3: Submit Prior Authorization Promptly

Virtually all Adalimumab prescriptions require PA. Delay is one of the biggest reasons patients can't access their medication on time. Best practices:

• Submit PA at the same time as the prescription — don't wait for a rejection
• Use electronic PA (ePA) through your EHR when available
• Include relevant clinical documentation upfront: diagnosis, prior treatments tried, lab results
• Follow up within 48 hours if no response

Step 4: Connect Patients with Manufacturer Support

Organon offers several programs that can help:

• $0 co-pay savings card: For eligible commercially insured patients — can reduce out-of-pocket costs to $0
• Organon Assist: Patient assistance program for uninsured or underinsured patients
• Patient support team: Can help locate pharmacies with Hadlima stock and navigate insurance issues

Direct patients to hadlima.com or have your staff help them enroll.

Step 5: Use Medfinder to Check Availability

Medfinder for Providers lets your team check which pharmacies have Hadlima in stock in real time. This can be integrated into your prescribing workflow:

• Before sending a prescription, check stock at the intended pharmacy
• If the preferred pharmacy is out, identify an alternative with availability
• Share Medfinder with patients so they can check stock independently for refills

Alternatives to Hadlima

If Hadlima is not accessible for a particular patient — whether due to formulary exclusion, unavailability, or patient preference — consider these alternatives:

• Amjevita (Adalimumab-atto): One of the earliest biosimilars to market; widely available
• Hyrimoz (Adalimumab-adaz): Sandoz product; citrate-free formulation available
• Cyltezo (Adalimumab-adbm): First interchangeable Adalimumab biosimilar — pharmacists can substitute without a new prescription in many states
• Humira (Adalimumab): The reference product; most widely stocked but significantly more expensive (WAC ~$6,922 vs. Hadlima's ~$1,038)

All Adalimumab products share the same mechanism of action, indications, and dosing. Switching between them is clinically supported by multiple studies. For a patient-facing comparison, see alternatives to Hadlima.

Workflow Tips for Your Practice

Implementing a few systematic changes can reduce Hadlima access problems across your patient panel:

Create a Biosimilar Quick Reference

Maintain a reference sheet for your clinical staff listing:

• Top 3-4 preferred Adalimumab biosimilars by major payers in your region
• Specialty pharmacy contact numbers for each major insurer
• Organon patient support phone number and website
• Medfinder URL: medfinder.com/providers

Standardize Your Biologic Prescribing Workflow

1. Check formulary preference
2. Write prescription for preferred product
3. Submit PA simultaneously
4. Route to specialty pharmacy
5. Enroll patient in co-pay program
6. Verify stock via Medfinder
7. Schedule follow-up within 2 weeks to confirm medication received

Educate Patients Proactively

At the time of prescribing, set expectations:

• Explain that Hadlima is a biologic that goes through a specialty pharmacy
• Warn them that the process takes longer than a regular prescription
• Give them their specialty pharmacy's contact information
• Encourage them to use Medfinder for refill planning

For more patient education resources, share our articles on what is Hadlima and Hadlima side effects.

Final Thoughts

Getting patients access to Hadlima is primarily a logistical challenge, not a clinical one. The medication is FDA-approved, competitively priced, and clinically equivalent to Humira. By building biosimilar-aware workflows into your practice — checking formularies, routing to specialty pharmacies, submitting PAs proactively, and using tools like Medfinder — you can significantly reduce access barriers for your patients.

The shift from brand biologics to biosimilars is one of the most impactful cost-containment opportunities in specialty care. Providers who embrace it can deliver the same clinical outcomes at dramatically lower costs — a win for patients, practices, and the healthcare system.

For the companion clinical briefing, see our Hadlima shortage update for providers.